Objectives: To estimate the total costs of treating head and neck cancers, specifically oropharyngeal, laryngeal and oral cavity cancer, in secondary care facilities in 
2 | ME TH ODS
| Ethical considerations
Approval for use of Hospital Episode Statistics (HES) data was granted by the Health and Social Care Information Centre. The individual HES records extracted contained no sensitive data and were pseudonymised, preventing the true identification of patients. Analyses pertaining to HES records adhered to published regulations. 15 The Health Research Authority decision tool stated no ethical approval was required for this research. Table 1 .
| Data analysis and statistical methods
A large proportion of payments made to secondary healthcare providers contracted by commissioners in England are governed by the Payment by Results (PbR) framework, 17 • Oropharyngeal cancer accounted for 37% of these costs and almost three-quarters of the costs were associated with the treatment of males.
• Between 2006/07 and 2010/11, inpatient numbers for the head and neck cancers discussed here increased by 25%.
consultant from admission to discharge, in some cases they are spread across a number of FCEs. A spell is also a more robust activity measure than a FCE as the latter can be easily influenced (eg, by transferring patients between consultants). Some key therapies in head and neck cancers do not have a National Tariff due to wide regional variation in costs and practice.
These therapies include (amongst others) chemotherapy, radiotherapy, palliative care and rehabilitation. Payments for these therapies are the product of local negotiations between commissioners and providers. For these costs, the relevant HRGs from HES were crossreferenced with the National Reference Costs and inflated using the pay cost index. 18 It was not possible to represent regional variation in these particular costs and for the purposes of presentation they were disaggregated from the core HRG to compartmentalise this uncertainty. The costs associated with the spell of care included all other costs associated with the initial diagnosis (if encountered in a hospital), surgical procedures and medical treatments.
Outpatient costs were estimated by grouping consultations by treatment specialty based on Treatment Function Codes (TFCs) and whether the consultation was the first of a series or a follow-up. As with the inpatient data, all activities for which reimbursement rates are locally negotiated, such as outpatient chemotherapy and radiotherapy sessions, were disaggregated from the core HRG.
To confirm whether there is evidence that costs have not increased uniformly with patient numbers, that is higher costs for newly diagnosed oropharyngeal patients, a difference in differences (DID) approach was utilised, with the t-test used to assess whether the means of the two groups were statistically different from each other. Oropharyngeal patients were taken to be the "treated" group, 
| RESULTS
Over the 5-year study period, the mean number of hospital spells per year attributed to the three cancer sites was 27 326, with a mean of 21 498 outpatient attendances per year in addition. The total costs of treatment for patients across all three sites were estimated to be around £309 million at 2011 prices ( Table 2 ). Just over 90% of these were the result of inpatient care covered by bundled HRGs (£280 million), with outpatient radiotherapy sessions accounting for the lowest proportion (£101 000; 0.03%). Costs due to oropharyngeal cancer were slightly higher than for the other two sites (£115 million; 37.06%), with laryngeal and oral cavity cancer accounting for 31.15% (£96 million) and 31.79% (£98 million), respectively. Inpatient costs were observed to be higher than outpatient costs for all reimbursement categories other than radiotherapy for oral cavity cancer.
Males were responsible for nearly three quarters (73.64%;
£227.77 million) of total treatment costs. The ratio of male to female costs was highest for laryngeal cancer at nearly 5:1 (£79.46 to £16.88 million), and lowest for oral cavity cancer at 1.6:1 (£61.10 to £37.23 million). The HES data showed that more resources were consumed during outpatient chemotherapy and radiotherapy for men compared to women, for both oropharyngeal and laryngeal cancer. In contrast, the reverse situation was observed for oral cavity cancer. However, as these categories comprised only a small proportion of the total cost burden, the overall distribution of costs between treatment settings for both genders remained broadly representative of that for the population collectively. respectively, over the course of the study, with inpatient numbers also increasing, by 372 (13%) and 502 (15%). Table 3 presents the mean values for the variables used in the DID analysis of the aggregate inpatient data. The results show there were no significant differences in the baseline period between the oropharyngeal and combined oral cavity and laryngeal groups in terms of total costs (P = .93) and total patients (P = .903). The results from the DID analysis can be found in Table 4 . Model 1 included a dummy variable for the male cohort, on which the coefficient was found to be positive and a strong predictor of higher costs (P < .01), and showed some indication of differences between the two groups (results not shown). In Model 2, the natural logarithm of total patient numbers was also included and found to be a significant predictor of higher total costs (P < .01) along with being male (P = .059), while also providing some evidence of a real difference between the two groups in the follow-up period (P = .053) (results not shown). However, there was no statistically significant evidence of a real change in differences between total costs for oropharyngeal and laryngeal/oral cavity cancer in either model 1 (P = .434) nor model 2 (P = .161). alone. These amounted to 27 326 spells of care and 4127 radiotherapy or chemotherapy delivery sessions on average per year, at a cost of over £300 million to the NHS. Although the per-patient costs for oropharyngeal cancer did not increase at a faster rate than for other head and neck cancer sites, we did observe a rapid increase in the number of patients being treated for this cancer (1420 more patients admitted to hospital in the final year of the study compared to the first, of which more than 1000 were male). This is consistent with data published elsewhere. 13 Our data also help highlight that head and neck cancers tend to disproportionately impact the male population who accounted for almost 75% of the total economic burden.
| DISCUSSION

| Key findings
| Strengths and limitations of the study
This research is the first to quantify the cost of treating head and neck cancers in England over time. The results provide important insights into how the cost burden for these cancers has changed over recent years, particularly for inpatient care where the data are most comprehensive.
The Audit Commission has stated that in 2012/13, only 4.1% of all outpatient attendances had a known primary diagnosis. 20 As this was our primary means of extracting information on patients with head and neck cancers, the figures for outpatient activity will not cover all consultations relating to the cancers under investigation and may be underestimated. Underestimation of inpatient costs is also likely to a lesser extent.
The HES database is heavily reliant on correct clinical coding and, as a result, data gaps have arisen. Although it was possible to assess a patient as having multiple hospital admissions from the data, it was not possible to distinguish between an initial or recurrent patient. The data did also not permit analysis of disease stage at presentation, which may in turn influence resource use. There has doubtless been an increased attention on the increasing incidence of oropharyngeal cancer, and parallel interest in the role of HPV as a major aetiological factor. As a consequence of this, it may be that the accuracy of coding, for example, site accuracy between oral cavity and oropharynx, may have increased over time but the effect of this on the relative incidence of oropharyngeal cancer is not quantifiable.
Together, the impact of these limitations, alongside the potential underestimation of outpatient costs and non-inclusion of indirect costs, result in our overall cost estimates most likely representing an underestimate of the true economic burden of treating head and neck cancers. 
| Clinical applicability of findings
The costing estimates presented here highlight that the cost burden of head and neck cancers is growing in England. The increasing pressure on NHS resources requires strategic investment for both treatment and prevention of these diseases. The observation that in 4 years, the number of patients with oropharyngeal cancer receiving some form of inpatient care has increased by more than half and the associated costs have increased by over three quarters reinforces the argument for prevention and early detection strategies to help contain these cost and health burdens.
The results of the present analyses suggest that the use of chemotherapy and radiotherapy in patients with oropharyngeal cancer has increased in recent years. It is not possible from the current data to determine why this is but greater use of chemotherapy and radiotherapy may have significant impacts on workforce and resource planning in head and neck oncology centres. It also highlights a need for better evidence from clinical trials in how to best manage this oropharyngeal cancer epidemic. 
T A B L E 4 Results of the differences in differences (DID) analysis
